Interview with Dr. Steven Nissan, principle investigator on the Lp(a) HORIZON trial.
Link to full interview:
radcliffeckm.comAha lpahorizon does lowering lpa reduce cv riskradcliffeckm.comQuoted from the original post:
Lp(a)HORIZON reports new phase 3 data on Lp(a) lowering and cardiovascular outcomes. Dr Steven Nissen and Dr Harriette Van Spall take a closer look at the primary results and extended cardiovascular outcomes analyses from Lp(a)HORIZON in this AHA 2026 Late-Breaker Trial Discussion.
The randomised, double-blind, placebo-controlled trial enrolled 8,323 patients with established cardiovascular disease and elevated lipoprotein(a). It evaluated an Lp(a)-lowering strategy against placebo, assessing major cardiovascular events including cardiovascular death, myocardial infarction, stroke and urgent coronary revascularisation.
Hear their perspectives on the findings and what Lp(a)HORIZON adds to the evidence around targeting elevated Lp(a) in established cardiovascular disease.
Watch the full interview here 🔗Aha lpahorizon does lowering lpa reduce cv risk (radcliffeckm.com)
This is an independent interview produced by Radcliffe Cardiology.


